<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542451</url>
  </required_header>
  <id_info>
    <org_study_id>07-199</org_study_id>
    <nct_id>NCT00542451</nct_id>
  </id_info>
  <brief_title>Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eric P Winer, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effect the postoperative combination of&#xD;
      therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer&#xD;
      recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node&#xD;
      positive and high risk node negative disease. This tests utilizes a well tolerated regimen of&#xD;
      weekly paclitaxel and trastuzumab in women with T1, node negative tumors that are HER2&#xD;
      positive. We would like to determine how effective this drug combination is when used in&#xD;
      women with early stage breast cancer, as well as to better define the side effects of this&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will enroll in this study at the time they are starting their adjuvant&#xD;
           therapy for breast cancer. Participants will receive chemotherapy with paclitaxel every&#xD;
           week for 12 weeks. They will begin to receive trastuzumab at the same time they begin&#xD;
           paclitaxel. Once they have completed the 12 weeks of paclitaxel and trastuzumab, they&#xD;
           will receive trastuzumab every 3 weeks or weekly for 40 weeks.&#xD;
&#xD;
        -  Participants will be followed with routine assessments such as physical exam and vital&#xD;
           signs every 3 months for the first year, and then every 6 months for years 2-5. Then we&#xD;
           would like to keep track of the participants medical condition by calling them on the&#xD;
           telephone once per year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate disease free survival (DFS) rate in patients with node-negative HER2-positive breast cancer with tumors less than or equal to 3cm treated with adjuvant trastuzumab and paclitaxel</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe DFS in patient groups defined by tumor size and hormone receptor status.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of grade III/IV cardiac left ventricular dysfunction from adjuvant trastuzumab and paclitaxel</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of grade III/IV neurotoxicity associated with adjuvant paclitaxel</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Topoisomerase II, cMYC, and p53 expression, and correlate with event rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate P13K mutations and PTEN alterations in a subset of patients and correlate events with the presence or absence of these mutations/alterations</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">420</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Carcinoma of the Breast</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Every week for 12 weeks</description>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks</description>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed invasive carcinoma of the breast&#xD;
&#xD;
          -  Tumors must be less than or equal to 3cm in greatest dimension&#xD;
&#xD;
          -  Must have node-negative breast cancer according to teh AJCC 7th edition&#xD;
&#xD;
          -  ER/PR determination is required. ER- and PR-assays should be performed by&#xD;
             immunohistochemical methods&#xD;
&#xD;
          -  HER-2 positive: IHC 3+ or FISH &gt;2&#xD;
&#xD;
          -  Bilateral breast cancers that individually meet eligibility criteria are allowed&#xD;
&#xD;
          -  Patients should have tumor tissue available, and a tissue block of sufficient size to&#xD;
             make 15 slides must be sent to DFCI for testing&#xD;
&#xD;
          -  Less than or equal to 84 days from mastectomy or from axillary dissection or sentinel&#xD;
             node biopsy if the patient's most extensive breast surgery was a breast-sparing&#xD;
             procedure&#xD;
&#xD;
          -  All tumor should be removed by either a modified radical mastectomy or a segmental&#xD;
             mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow function, hepatic function, and renal function as outlined in&#xD;
             protocol&#xD;
&#xD;
          -  Left ventricular ejection fraction of greater than or equal to 50%&#xD;
&#xD;
          -  Willingness to discontinue any hormonal agent prior to registration and while on study&#xD;
&#xD;
          -  Willingness to discontinue sex hormonal therapy, e.g. birth control pills, prior to&#xD;
             registration and while on study&#xD;
&#xD;
          -  Patients with a history of ipsilateral DCIS are eligible if they were treated with&#xD;
             wide-excision alone, without radiation therapy&#xD;
&#xD;
          -  Patients undergoing breast conservation therapy must not have any contraindications to&#xD;
             radiation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau&#xD;
             d'orange, skin ulcerations/nodules, or clinical inflammatory changes&#xD;
&#xD;
          -  History of prior chemotherapy in past 5 years&#xD;
&#xD;
          -  History of prior trastuzumab therapy&#xD;
&#xD;
          -  Active, unresolved infection&#xD;
&#xD;
          -  Prior history of any other malignancy in the past 5 years, except for early stage&#xD;
             tumors of the skin or cervix treated with curative intent&#xD;
&#xD;
          -  Sensitivity to benzyl alcohol&#xD;
&#xD;
          -  Grade 2 or greater neuropathy per NCI's CTCAv3.0. (Exception: Any chronic neurologic&#xD;
             disorder will be looked at on a case-by-case basis by the study chair).&#xD;
&#xD;
          -  Active cardiac disease as outlined in protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Winer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Healthcare</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowelll General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Medical Center</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore LIJ Health System Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennesse Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2007</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Eric P Winer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>node-negative breast cancer</keyword>
  <keyword>HER-2 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

